{"title":"VYC-25L在成人矫正下颌后缩中增强下颌轮廓安全有效。","authors":"Yun Xie, Qingfeng Li, Hongyi Zhao, Zuoliang Qi, Jiaming Sun, Qian Tan, Dong Li, Zhiqi Hu, Ziyang Liu, Smita Chawla","doi":"10.1093/asj/sjaf033","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with chin retrusion may seek chin and lower jawline aesthetic enhancement.</p><p><strong>Objectives: </strong>To evaluate VYC-25L (Juvéderm Volux XC; Allergan Aesthetics, an AbbVie company), a lidocaine-containing injectable hyaluronic acid dermal filler, for chin retrusion correction.</p><p><strong>Methods: </strong>In this prospective, Phase 3, multicenter study (NCT04559984), Chinese adults with moderate-to-severe chin retrusion on the China (Allergan) Chin Retrusion Scale (CACRS) and glabella-subnasale-pogonion (G-Sn-Pog) angle <172.5° were randomized 2:1 to VYC-25L (treatment plus optional touch-up 4 weeks later) or no treatment (control). The primary endpoint was change from baseline (CFB) in G-Sn-Pog angle at Week 24. Secondary endpoints included CACRS response (≥1-point improvement), Global Aesthetic Improvement Scale (GAIS) response (improved/much improved), and FACE-Q Satisfaction with Chin score. Procedural pain was rated (0 = none to 10 = worst imaginable); injection-site responses (ISRs) were recorded daily for ≤28 days.</p><p><strong>Results: </strong>The mean age of the patient (VYC-25L, n = 97; control, n = 51) was 31.2 years (range, 20-52 years). Mean CFB in G-Sn-Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control; between-group difference, 3.08° [P < .0001]); improvement was maintained to Week 52. At Week 24, VYC-25L achieved higher responses vs control for CACRS (78.7% vs 18.8%, respectively; rate difference, 60.0%; P < .0001) and GAIS (92.6% vs 4.2%, respectively; rate difference, 88.4%; P < .0001); mean overall FACE-Q Satisfaction with Chin score was 70.4 vs 34.9, respectively. Mean (standard deviation) procedural pain was 2.6 (1.6); most ISRs were mild (41.8%) or moderate (50.0%) in severity.</p><p><strong>Conclusions: </strong>In Chinese adults, VYC-25L safely and effectively corrected chin retrusion for at least 1 year.</p><p><strong>Level of evidence: 2 (therapeutic): </strong></p>","PeriodicalId":7728,"journal":{"name":"Aesthetic Surgery Journal","volume":" ","pages":"699-708"},"PeriodicalIF":3.0000,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168443/pdf/","citationCount":"0","resultStr":"{\"title\":\"VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults.\",\"authors\":\"Yun Xie, Qingfeng Li, Hongyi Zhao, Zuoliang Qi, Jiaming Sun, Qian Tan, Dong Li, Zhiqi Hu, Ziyang Liu, Smita Chawla\",\"doi\":\"10.1093/asj/sjaf033\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Individuals with chin retrusion may seek chin and lower jawline aesthetic enhancement.</p><p><strong>Objectives: </strong>To evaluate VYC-25L (Juvéderm Volux XC; Allergan Aesthetics, an AbbVie company), a lidocaine-containing injectable hyaluronic acid dermal filler, for chin retrusion correction.</p><p><strong>Methods: </strong>In this prospective, Phase 3, multicenter study (NCT04559984), Chinese adults with moderate-to-severe chin retrusion on the China (Allergan) Chin Retrusion Scale (CACRS) and glabella-subnasale-pogonion (G-Sn-Pog) angle <172.5° were randomized 2:1 to VYC-25L (treatment plus optional touch-up 4 weeks later) or no treatment (control). The primary endpoint was change from baseline (CFB) in G-Sn-Pog angle at Week 24. Secondary endpoints included CACRS response (≥1-point improvement), Global Aesthetic Improvement Scale (GAIS) response (improved/much improved), and FACE-Q Satisfaction with Chin score. Procedural pain was rated (0 = none to 10 = worst imaginable); injection-site responses (ISRs) were recorded daily for ≤28 days.</p><p><strong>Results: </strong>The mean age of the patient (VYC-25L, n = 97; control, n = 51) was 31.2 years (range, 20-52 years). Mean CFB in G-Sn-Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control; between-group difference, 3.08° [P < .0001]); improvement was maintained to Week 52. At Week 24, VYC-25L achieved higher responses vs control for CACRS (78.7% vs 18.8%, respectively; rate difference, 60.0%; P < .0001) and GAIS (92.6% vs 4.2%, respectively; rate difference, 88.4%; P < .0001); mean overall FACE-Q Satisfaction with Chin score was 70.4 vs 34.9, respectively. Mean (standard deviation) procedural pain was 2.6 (1.6); most ISRs were mild (41.8%) or moderate (50.0%) in severity.</p><p><strong>Conclusions: </strong>In Chinese adults, VYC-25L safely and effectively corrected chin retrusion for at least 1 year.</p><p><strong>Level of evidence: 2 (therapeutic): </strong></p>\",\"PeriodicalId\":7728,\"journal\":{\"name\":\"Aesthetic Surgery Journal\",\"volume\":\" \",\"pages\":\"699-708\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12168443/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aesthetic Surgery Journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/asj/sjaf033\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aesthetic Surgery Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/asj/sjaf033","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
摘要
背景：有下巴后缩的个体可能会寻求下巴和下颚线的美学增强。目的：评价VYC-25L (juv2013.2013.09；Allergan Aesthetics（艾伯维公司），一种含有利多卡因的注射透明质酸真皮填充剂，用于矫正下巴后缩。方法：在这项前瞻性3期多中心研究（NCT04559984）中，中国（Allergan）中国（Allergan）下巴后缩量表（CACRS）和眉间-鼻下-毒瘤（G-Sn-Pog）角度中至重度下巴后缩的中国成年人。对照组（n = 51）为31.2岁（范围20-52岁）。第24周G-Sn-Pog角平均CFB为2.97°（VYC-25L） vs 0.09°(对照组；组间差异为3.08°[P < .0001])；改善持续至第52周。在第24周，VYC-25L治疗CACRS的应答率高于对照组（分别为78.7%和18.8%）；率差60.0%；P < 0.0001)和GAIS(分别为92.6% vs 4.2%；差别率为88.4%；P < 0.0001)；FACE-Q对中国的总体满意度分别为70.4分和34.9分。平均（标准差）程序性疼痛为2.6 (1.6)；大多数isr为轻度（41.8%）或中度（50.0%）。结论：在中国成人中，VYC-25L安全有效地矫正下颌后缩至少1年。证据等级：2（治疗性）：
VYC-25L Is Safe and Effective for Enhancing the Chin and Jawline by Correcting Chin Retrusion in Chinese Adults.
Background: Individuals with chin retrusion may seek chin and lower jawline aesthetic enhancement.
Objectives: To evaluate VYC-25L (Juvéderm Volux XC; Allergan Aesthetics, an AbbVie company), a lidocaine-containing injectable hyaluronic acid dermal filler, for chin retrusion correction.
Methods: In this prospective, Phase 3, multicenter study (NCT04559984), Chinese adults with moderate-to-severe chin retrusion on the China (Allergan) Chin Retrusion Scale (CACRS) and glabella-subnasale-pogonion (G-Sn-Pog) angle <172.5° were randomized 2:1 to VYC-25L (treatment plus optional touch-up 4 weeks later) or no treatment (control). The primary endpoint was change from baseline (CFB) in G-Sn-Pog angle at Week 24. Secondary endpoints included CACRS response (≥1-point improvement), Global Aesthetic Improvement Scale (GAIS) response (improved/much improved), and FACE-Q Satisfaction with Chin score. Procedural pain was rated (0 = none to 10 = worst imaginable); injection-site responses (ISRs) were recorded daily for ≤28 days.
Results: The mean age of the patient (VYC-25L, n = 97; control, n = 51) was 31.2 years (range, 20-52 years). Mean CFB in G-Sn-Pog angle at Week 24 was 2.97° (VYC-25L) vs 0.09° (control; between-group difference, 3.08° [P < .0001]); improvement was maintained to Week 52. At Week 24, VYC-25L achieved higher responses vs control for CACRS (78.7% vs 18.8%, respectively; rate difference, 60.0%; P < .0001) and GAIS (92.6% vs 4.2%, respectively; rate difference, 88.4%; P < .0001); mean overall FACE-Q Satisfaction with Chin score was 70.4 vs 34.9, respectively. Mean (standard deviation) procedural pain was 2.6 (1.6); most ISRs were mild (41.8%) or moderate (50.0%) in severity.
Conclusions: In Chinese adults, VYC-25L safely and effectively corrected chin retrusion for at least 1 year.
期刊介绍：
Aesthetic Surgery Journal is a peer-reviewed international journal focusing on scientific developments and clinical techniques in aesthetic surgery. The official publication of The Aesthetic Society, ASJ is also the official English-language journal of many major international societies of plastic, aesthetic and reconstructive surgery representing South America, Central America, Europe, Asia, and the Middle East. It is also the official journal of the British Association of Aesthetic Plastic Surgeons, the Canadian Society for Aesthetic Plastic Surgery and The Rhinoplasty Society.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
